To the full analysis
Bio-Techne stock: growth
TECHBio-Techne reported $1.22B in revenue for fiscal 2026, down 0.4% on the prior year, up 5.5% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
9.3%
per year from 2007 to 2026, per share 9.4%
Earnings (Annual rate)
4.1%
per year from 2007 to 2026, per share 4.2%
Free cash flow (Annual rate)
6.3%
per year from 2007 to 2026, per share 6.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 5.5% | 9.3% | 9.3% |
| Revenue per share | 5.3% | 8.8% | 9.4% |
| Earnings | 5.3% | 5.7% | 4.1% |
| Earnings per share | 5.2% | 5.3% | 4.2% |
| Free cash flow | −3.1% | 7.6% | 6.3% |
| Free cash flow per share | −3.2% | 7.1% | 6.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $223.48M | $85.11M | $82.43M |
| 2008 | $257.42M | $103.56M | $98.95M |
| 2009 | $263.96M | $105.24M | $104.77M |
| 2010 | $269.05M | $109.78M | $106.62M |
| 2011 | $289.96M | $112.3M | $123.56M |
| 2012 | $314.56M | $112.33M | $120.73M |
| 2013 | $310.58M | $112.56M | $101.11M |
| 2014 | $357.76M | $110.95M | $122.94M |
| 2015 | $452.25M | $107.74M | $119.45M |
| 2016 | $499.02M | $104.48M | $126.97M |
| 2017 | $563M | $77.29M | $128.27M |
| 2018 | $642.99M | $125.35M | $149.43M |
| 2019 | $714.01M | $96.07M | $156.21M |
| 2020 | $738.69M | $229.3M | $153.47M |
| 2021 | $931.03M | $140.41M | $307.86M |
| 2022 | $1.11B | $272.05M | $280.36M |
| 2023 | $1.14B | $285.26M | $216.15M |
| 2024 | $1.16B | $168.11M | $236.1M |
| 2025 | $1.22B | $73.4M | $256.55M |
| 2026 | $1.22B | $181.86M | $263.22M |
Revenue by segment
How Bio-Techne Corporation makes its money and how that has shifted. Names are as the company reports them.
- Consumables81%
- Instruments9%
- Royalty2%
- Other8%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|
| Consumables | $917.73M | $928.18M | $972.29M | $985.12M | 81.1% |
| Instruments | $112.09M | $108.27M | $112.09M | $110.63M | 9.1% |
| Royalty | $21.1M | $23.35M | $23.69M | $24.99M | 2.1% |
| Other | $85.78M | $99.27M | $111.57M | $94.3M | 7.8% |
| Total revenue | $1.14B | $1.16B | $1.22B | $1.22B | 100% |
Revenue by region
Where Bio-Techne Corporation generates its revenue.
- United States52%
- Europe24%
- C N9%
- APAC, excluding Greater China7%
- United Kingdom5%
- Rest of world3%
Figures as a table
| 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|
| United States | $642.47M | $657.75M | $683.23M | $635.37M | 52.3% |
| Europe | $220.23M | $241.43M | $266.31M | $294.22M | 24.2% |
| C N | $113.87M | $99.47M | $100.46M | $104.06M | 8.6% |
| APAC, excluding Greater China | $73.19M | $73.9M | $77.26M | $85.82M | 7.1% |
| United Kingdom | $49.46M | $50.01M | $54.83M | $56.28M | 4.6% |
| Rest of world | $37.49M | $36.5M | $37.55M | $39.29M | 3.2% |
| Total revenue | $1.14B | $1.16B | $1.22B | $1.22B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.